73MO Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE study

Y.J Kim,M Kudo,K-K Kuo,N Kato,Y Mao,S-B Cho,G Shao,S Qin,H.Y Lim,M Kurosaki,K Ozgurdal,K Numata,B Chewaskulyong,M Ikeda,Y-H Huang ,Long-Bin Jeng ,Jean-Emmanuel Khan ,Lin Shen ,Chao‐Ping Hsu ,Doyoung Kim

doi:10.1016/j.annonc.2022.10.109

73MO Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE study

Y.J Kim, M Kudo + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.109

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2022
Citations: 1	License type: publisher-specific-oa

Affiliation: Seoul National University Hospital

#Asian Pts #Regorafenib In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In an interim analysis of Asian pts with uHCC in the observational REFINE study of regorafenib (NCT03289273), treatment-emergent adverse events (TEAEs) were consistent with those reported in the global, phase 3 RESORCE trial. Here, we present the final analysis of Asian pts with uHCC in REFINE.

Full Text